rethinkPeptides Search
Menu
Home / Research library
Study breakdown

BNP and Endothelin Predict Heart Failure Death at Different Disease Stages

RPEP-007942003Berger, Rudolf; Strecker, Karin; Huelsmann, Martin; Moser, Petra; Frey, Bernhard; Bojic, Anja; Stanek, Brigitte; Pacher, Richard
CohortStrong evidence
The takeaway

BNP and endothelin have different prognostic strengths depending on heart failure stage and follow-up duration — BNP predicts early outcomes in mild HF while endothelin predicts long-term outcomes in advanced HF.

Stage matters

BNP predicts best in mild-moderate HF; endothelin in advanced HF — the right biomarker depends on disease stage

What the researchers found

BNP best predicted short-term outcomes in mild-moderate heart failure, while endothelin was more prognostic in advanced heart failure and over longer follow-up, demonstrating stage- and time-dependent prognostic value of neurohormonal biomarkers.

Why it matters

Choosing the right biomarker for risk prediction depends on context. BNP is best for early-stage risk assessment, while endothelin adds value in advanced disease — precision prognosis.

How the study worked

Prospective cohort study measuring BNP, NT-proBNP, ANP, and endothelin in CHF patients across NYHA classes II-IV. Prognostic power assessed for different disease stages and follow-up periods.

What this study cannot tell us

Observational cohort. Specific cutoffs and time horizons may vary between populations. Multi-marker panels add cost and complexity.

How to read the evidence

Strong evidence from a prospective cohort with comprehensive multi-marker and multi-stage prognostic analysis.

When this study was published

Published in 2003. Stage-dependent biomarker selection in heart failure continues to guide clinical practice.

The bigger picture

Precision medicine in heart failure means using the right tool at the right time. A BNP level means something different in mild versus advanced heart failure, and the best predictor changes with disease evolution.

Questions still open

  • Should different biomarkers be used at different heart failure stages?
  • Can sequential biomarker panels track disease progression?
  • Does endothelin-guided therapy improve advanced HF outcomes?

Common questions

Is one blood test enough to predict heart failure outcomes?
No — this study shows different biomarkers work best at different disease stages. BNP predicts well early on, but endothelin becomes more important as heart failure advances.
Why use different markers at different stages?
Because the dominant disease mechanism changes as heart failure progresses. Early HF involves volume overload (BNP), while advanced HF involves vascular dysfunction (endothelin). Matching the marker to the mechanism improves prediction.

Read the original research

Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 22(9), 1037-45

View on PubMed ↗

Citation

Berger, Rudolf; Strecker, Karin; Huelsmann, Martin; Moser, Petra; Frey, Bernhard; Bojic, Anja; Stanek, Brigitte; Pacher, Richard. (2003). Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period.. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 22(9), 1037-45.